As proof of concept, targeting VLA-4 (α4) disrupts the VCAM1–VLA-4 interactions between CTC and immunosuppressive DPT and inhibits metastasis, ultimately improving breast cancer outcomes. Here, VCAM1 is linked to breast carcinoma.